Section
This review synthesizes findings from a Phase 2 trial of ICP-332, a novel TYK2 inhibitor, demonstrating significant EASI score improvements and a manageable safety profile in moderate to severe atopic dermatitis.
This study identifies activating EGFR L858R variants as the genetic basis for a syndrome featuring generalized acanthosis nigricans and lung nodules, highlighting the efficacy of EGFR inhibitors in treating both cutaneous and systemic manif
A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighti
A large-scale multicentre clinical trial reveals that 5% permethrin cream is significantly more effective than oral ivermectin for treating scabies in households, providing crucial evidence for public health and clinical practice.
A Phase II trial demonstrates that combining lenvatinib with pembrolizumab prior to surgery in Merkel cell carcinoma results in a 57.7% pathological complete response rate, suggesting a highly effective new strategy for managing resectable
The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, high
The Phase 3 VIITAL trial demonstrates that prademagene zamikeracel, an autologous gene-modified cellular sheet, significantly improves healing and reduces pain in patients with recessive dystrophic epidermolysis bullosa (RDEB), offering a t
A Phase IIB trial demonstrates that denovoSkin™, an autologous bio-engineered skin graft, offers a significantly higher expansion ratio and superior scar outcomes compared to split-thickness skin grafts in burn patients, potentially revolut
A randomized double-blind trial reveals that EMG-guided Onabotulinum toxin A injections effectively alleviate pain and enhance quality of life and sexual satisfaction in women with provoked vestibulodynia, supporting the role of muscular hy
Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemi
A cohort study validates PROMIS measures for anxiety, depression, and social impact in chronic skin diseases, demonstrating that these standardized tools are reliable for tracking physical and social outcomes in clinical dermatology setting
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
A single-center perspective-controlled trial found subcutaneous low-dose IL-2 plus corticosteroids achieved faster disease control in moderate-to-severe bullous pemphigoid and reduced total steroid exposure without serious infections, suppo
Two global phase 3 trials show rocatinlimab, an anti‑OX40 therapy, produced statistically significant improvements in EASI‑75 and vIGA‑AD 0/1 at 24 weeks versus placebo with a generally acceptable safety profile.
A large UK cohort study developed and externally validated a 100‑day prognostic model for allopurinol‑induced severe cutaneous adverse reactions (SCAR). Key predictors include age, CKD stage, high initial dose, and Asian ethnicity; discrimi
An international Delphi consensus produced standardized morphological definitions and practical guidance to improve investigator lesion assessment in hidradenitis suppurativa clinical trials, enhancing reliability and trial data quality.
A multidisciplinary Delphi panel produced consensus morphological definitions and practical guidance to standardize investigator lesion assessments in hidradenitis suppurativa (HS) clinical trials — improving reliability of endpoints such a
The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short m
Lupuslike manifestations linked with MDS and CMML differ greatly from classic lupus, featuring unique clinical and molecular traits and often requiring clone-directed treatment rather than standard lupus therapies.
Two large US retrospective cohort studies show seborrheic dermatitis is strongly associated with a range of epithelial barrier diseases (skin, respiratory, gastrointestinal, ocular), with evidence of bidirectional risk. Findings support the
